Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 29, 2003
Business Overview: Illumina develops next-generation tools for large-scale genetic analysis, including the BeadArray technology platform. The company sells custom oligonucleotides, array matrices, assay reagents, and genotyping systems (BeadLab), and provides SNP genotyping services. The company is in the early stages of commercialization and has incurred substantial operating losses since inception.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 29, 2003 |
Six Months Ended June 29, 2003 |
Six Months Ended June 30, 2002 |
|---|---|---|---|
| Total Revenue | $4,769 | $9,045 | $3,169 |
| Net Loss | $(8,592) | $(17,552) | $(25,114) |
| Net Loss Per Share (Basic/Diluted) | $(0.27) | $(0.55) | $(0.82) |
| Cash and Cash Equivalents | $6,466 | $6,466 | $705 |
| Total Investments (Available for Sale) | $33,628 | $33,628 | $51,727 |
| Restricted Cash and Investments | $12,428 | $12,428 | $12,530 |
| Total Debt (Current + Long-term) | $25,531 | $25,531 | $25,707 |
| Accumulated Deficit | $108.0 million (as of June 29, 2003) |
Liquidity: As of June 29, 2003, the company held approximately $52.5 million in cash, cash equivalents, and investments. Approximately $12.5 million of marketable securities are restricted as collateral for a litigation surety bond.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the six months ended June 29, 2003, increased to $9.0 million from $3.2 million in the prior year period. This 186% increase was driven by the first sales of the BeadLab SNP genotyping system and growth in SNP genotyping services.
- Product Mix Shift: Product revenue rose to $4.1 million (six months 2003) from $1.6 million (six months 2002). Service revenue increased significantly to $3.3 million from $0.1 million.
- Reduced Losses: Net loss for the six months ended June 29, 2003, was $17.6 million, a decrease from $25.1 million in the same period in 2002. The improvement is largely attributable to the absence of the $7.7 million litigation judgment recorded in the second quarter of 2002.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased to $8.7 million (six months 2003) from $3.9 million (six months 2002), primarily due to higher legal fees related to the Applied Biosystems dispute and expanded sales/marketing efforts. Research and development expenses decreased to $11.9 million from $14.1 million.
- Cash Flow: Net cash used in operating activities decreased to $12.1 million (six months 2003) from $13.6 million (six months 2002). Investing activities provided $16.5 million in cash due to maturities of investment securities, contrasting with a $15.9 million use of cash in the prior year period driven by facility purchases.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects to continue incurring substantial operating losses and negative cash flow for the foreseeable future. The company anticipates that current capital resources will fund operations for at least 18 to 24 months. Significant revenue growth is required to achieve profitability.
- Legal Contingencies (Applied Biosystems):
- Patent Infringement: Applied Biosystems sued Illumina for patent infringement regarding the GoldenGate assay. Illumina seeks damages and an injunction; the federal court stayed the complaint in July 2003.
- Breach of Contract/Arbitration: Applied Biosystems alleges breach of a 1999 joint development agreement, seeking $30 million in damages and disgorgement of revenues. Illumina countersued for breach of contract and fraudulent inducement. A preliminary injunction preventing arbitration was granted in February 2003. An evidentiary hearing is scheduled for September 2003.
- Deferred Revenue: $10 million in non-refundable research funding from Applied Biosystems remains classified as deferred revenue until the legal status of the collaboration is resolved.
- Legal Contingencies (Employment Litigation): A $7.7 million judgment from a termination-of-employment lawsuit remains on appeal. Illumina has posted a surety bond of approximately $11.3 million, secured by restricted investments of $12.5 million. Interest on the judgment is being accrued.
- Risks: Key risks include the inability to achieve profitability, dependence on the commercial success of new technologies (BeadLab, BeadChip), intense competition, potential inability to secure additional capital, and the outcome of ongoing litigation which could materially adversely affect the business.
Investor Verification Checklist
- Litigation Resolution: Monitor the status of the Applied Biosystems patent and contract disputes, as a negative outcome could result in significant damages or injunctions against core products.
- Restricted Assets: Verify the release of the $12.5 million in restricted investments currently held as collateral for the employment litigation appeal.
- Revenue Sustainability: Assess whether the revenue growth from the initial BeadLab system sales is sustainable or if it represents a one-time spike, given the company's reliance on large, individual transactions.
- Cash Burn Rate: Track the rate of cash consumption against the stated 18-24 month runway to determine the timing and necessity of future capital raises.
- Deferred Revenue Recognition: Confirm the conditions under which the $10 million deferred revenue from Applied Biosystems might be recognized or written off.